Brainstorm Cell Therapeutics Inc. (BCLI) completed a $1 million strategic private placement, pricing shares at $0.60 each—a premium to the prevailing market price of $0.54 at the time of announcement. The financing structure includes warrant coverage at 120% of the placement amount, with warrants exercisable at $1.00 per share, providing investors with additional upside participation.
The company indicated that proceeds from the offering will be allocated toward advancing regulatory initiatives and funding its Phase 3b clinical trial program for NurOwn®, the company's investigational cell-based therapy for amyotrophic lateral sclerosis (ALS). This capital raise supports Brainstorm's continued development of its pipeline as it progresses through late-stage clinical testing.
The strategic financing underscores investor confidence in the company's clinical development trajectory, with the pricing premium reflecting terms negotiated above contemporary market levels. The warrant component provides participants with potential equity upside contingent upon share price appreciation to $1.00 or higher.